Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2010 Mar;25(1):27-35.
doi: 10.3904/kjim.2010.25.1.27. Epub 2010 Feb 26.

Comparative study of low doses of rosuvastatin and atorvastatin on lipid and glycemic control in patients with metabolic syndrome and hypercholesterolemia

Jong-Seon Park  1 , Young-Jo Kim, Ji-Yong Choi, Yoon-Nyun Kim, Teck-Jong Hong, Dong-Soo Kim, Ki-Young Kim, Myung-Ho Jeong, Jei-Keon Chae, Seok-Kyu Oh, In-Whan Seong
Affiliations
Randomized Controlled Trial

Comparative study of low doses of rosuvastatin and atorvastatin on lipid and glycemic control in patients with metabolic syndrome and hypercholesterolemia

Jong-Seon Park et al. Korean J Intern Med. 2010 Mar.

Abstract

Background/aims: This multicenter, open-labeled, randomized trial was performed to compare the effects of rosuvastatin 10 mg and atorvastatin 10 mg on lipid and glycemic control in Korean patients with nondiabetic metabolic syndrome.

Methods: In total, 351 patients who met the modified National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) criteria for metabolic syndrome with low-density lipoprotein cholesterol (LDL-C) levels > or = 130 mg/dL were randomized to receive either rosuvastatin 10 mg (n = 173) or atorvastatin 10 mg (n = 178) for over 6 weeks.

Results: After 6 weeks of treatment, greater reductions in total cholesterol (- 35.94 +/- 11.38 vs. - 30.07 +/- 10.46%, p < 0.001), LDL-C (48.04 +/- 14.45 vs. 39.52 +/- 14.42%, p < 0.001), non-high-density lipoprotein cholesterol (- 42.93 +/- 13.15 vs. - 35.52 +/- 11.76%, p < 0.001), and apolipoprotein-B (- 38.7 +/- 18.85 vs. - 32.57 +/- 17.56%, p = 0.002) levels were observed in the rosuvastatin group as compared to the atorvastatin group. Overall, the percentage of patients attaining the NCEP ATP III goal was higher with rosuvastatin as compared to atorvastatin (87.64 vs. 69.88%, p < 0.001). Changes in glucose and insulin levels, and homeostasis model assessment of insulin resistance index were not significantly different between the two groups. The safety and tolerability of the two agents were similar.

Conclusions: Rosuvastatin 10 mg was more effective than atorvastatin 10 mg in achieving NCEP ATP III LDL-C goals in patients with nondiabetic metabolic syndrome, especially in those with lower NCEP ATP III target level goals.

Keywords: Atorvastatin; Hypercholesterolemia; Metabolic syndrome X; Rosuvastatin.

PubMed Disclaimer

Conflict of interest statement

No potential conflict of interest relevant to this article was reported.

Figures

Figure 1
Figure 1
Trial design. LDL, low-density lipoprotein; HDL, high-density lipoprotein.
Figure 2
Figure 2
Percent change of lipid and apolipoprotein after treatment for 6 weeks. LDL-C, low-density lipoprotein cholesterol; Total-C, total cholesterol; HDL-C, high-density lipoprotein cholesterol; Apo, apolipoprotein.
Figure 3
Figure 3
Proportions of patients reaching different Adult Treatment Panel III, low-density lipoprotein cholesterol (LDL-C) level goals at 6 weeks after treatment. aProportion of patients reaching LDL-C level goal < 100, 130 or 160 mg/dL depending on risk category at baseline.
See this image and copyright information in PMC

References

    1. Brewer HB., Jr New features of the National Cholesterol Education Program Adult Treatment Panel III lipid-lowering guidelines. Clin Cardiol. 2003;26(4 Suppl 3):III19–III24. - PMC - PubMed
    1. Kwon HS, Park YM, Lee HJ, et al. Prevalence and clinical characteristics of the metabolic syndrome in middle-aged Korean adults. Korean J Intern Med. 2005;20:310–316. - PMC - PubMed
    1. Kim YK. Impact of the metabolic syndrome and its components on pulse wave velocity. Korean J Intern Med. 2006;21:109–115. - PMC - PubMed
    1. Boden WE. Therapeutic implications of recent ATP III guidelines and the important role of combination therapy in total dyslipidemia management. Curr Opin Cardiol. 2003;18:278–285. - PubMed
    1. Yood MU, McCarthy BD, Kempf J, et al. Racial differences in reaching target low-density lipoprotein goal among individuals treated with prescription statin therapy. Am Heart J. 2006;152:777–784. - PubMed

Publication types

MeSH terms